Clinical Trial Update: Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cabozantinib with androgen ablation in androgen-dependent metastatic prostate cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-03-25